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The S100 protein family contains 20 functionally expressed members, which are commonly dysregulated in
cancer. Their wide range of functions includes cell proliferation, cell differentiation, regulation of transcription
factors, inflammation, chemotaxis, and angiogenesis. S100 proteins have in several types of cancer proven to be
biomarkers for disease progression and prognosis. Acute myeloid leukemia (AML) is a highly heterogeneous and
aggressive disease in which immature myeloblasts replace normal hematopoietic cells in the bone marrow. This
review focuses on the S100 protein family members, which commonly are dysregulated in AML, and on the
consequences of their dysregulation in the disorder. Like in other cancers, it appears as if S100 proteins are
potential biomarkers for leukemogenesis. Furthermore, several S100 members seem to be involved in maintaining
the leukemic phenotype. For these reasons, specific S100 proteins might serve as prognostic biomarkers,
especially in the patient subset with intermediate/undetermined risk, and as potential targets for patient-adjusted
therapy. Because the question of the most suitable candidate S100 biomarkers in AML still is under discussion,
because particular AML subgroups lead to specific S100 signatures, and because downstream effects and the
significance of co-expression of potential S100 binding partners in AML are not fully elucidated yet, we conclude
that a panel of S100 proteins will probably be best suited for prognostic purposes.
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Acute myeloid leukemia (AML) comprises a biologically and
genetically heterogeneous group of disorders characterized by an
accumulation of immature myeloblasts in the bone marrow [1,2].
These blasts proliferate rapidly and have a block in differentiation and
increased resistance towards apoptosis; as a result, they outgrow
normal hematopoietic cells. The median age at diagnosis is about
65 years, and in most cases, AML occurs de novo; but AML can also
be treatment-related or be secondary to myelodysplastic syndromes
(MDSs) or myeloproliferative neoplasia [3]. The backbone of AML
treatment for younger/fit patients is induction therapy with
cytarabine in combination with an anthracyclin, followed by
consolidation therapy [4]. Due to a high rate of relapse, the overall
5-year survival is below 50% also for those patients who can receive
the most intensive treatment; for the remaining patients, the
prognosis is even worse [4,5].
AML is highly heterogeneous with regard to cell morphology,
cytogenetics, and gene mutations. More mature blasts are character-
ized by their loss of the stem cell marker CD34 [6]. Morphologically,AML has been divided into eight distinct groups in the FAB system
(FAB M0-M7), where the cells are categorized as showing no/
minimal signs of differentiation (FAB M0/M1) or presenting a more
mature phenotype (FAB M5-7) [7]. Out of these groups, only FAB
M3 — acute promyelocytic leukemia (APL) — entails its own
treatment regimen [8] and is now considered by hematologists as a
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50%-60% of AML patients carry chromosomal alterations, which
are divided into low/favorable, intermediate, and high/adverse risk
[2,8]. Finally, more than half of the patients show gene mutations in
their leukemic cells, with FMS-related tyrosine kinase 3-internal
tandem duplications (Flt3-ITD, negative prognosis) and nucleophos-
min insertions (NPM1-ins, positive prognosis in absence of
Flt3-ITD) being the most prominent [4,9]. In recent years, mutations
in isocitrate dehydrogenases 1 and 2 (IDH1/2), which are present in
about 20% of AML patients, have been particularly in the focus of
research (e.g., [10,11]).
Due to its aggressiveness and still abysmal outcome as compared to,
for instance, childhood acute lymphoblastic leukemia (ALL), there is a
need for more patient-adjusted therapy than standard induction and
consolidation treatment in AML. Furthermore, because AML is highly
heterogeneous, identifying predictive biomarkers and/or targets that are
common across AML subgroups would be of great value. S100 proteins
might have the potential to predict prognosis in, for instance, the
patients who fall in the relatively large AML category with intermediate
risk or to aid as suitable targets for tailored antileukemic treatment.
The S100 Protein Family
Structure and Function
The S100 protein family is restricted to vertebrates and comprises
20 functionally expressed proteins. Additionally, the related S100
fused type protein (SFTP) family contains seven members. The
S100A subgroup (S100A1-S100A16, where S100A15 has been
renamed into S100A7A as it proved to be a paralog of S100A7 [12]),
together with the SFTP family, is encoded on chromosome 1q21 in
the so-called epidermal differentiation complex, a hotspot for
genomic rearrangements [13,14]. The remaining four members are
spread throughout the genome: S100B is encoded on chromosome
21; S100G is encoded on the X chromosome; S100P is encoded on
chromosome 4; and, finally, S100Z is located to chromosome 5 [15].
S100 proteins exist as monomers, homo- and heterodimers, and
multimers; the various forms employ distinct functions, e.g.,
extracellular functions appear to be conducted by oligomers [16]. The
protein family, with exception of S100A10 [15], binds Ca2+ — and
some members additionally can bind Zn2+, Cu2+, and Mn2+ [17] —
when high levels of calcium are available, which is in contrast to
constitutively expressed Ca2+-binding proteins like calmodulin [18].
Each S100 protein contains two Ca2+-binding helix-loop-helix motifs,
so-called EF-hands [19]. The C-terminal, canonical EF-hand contains
12 amino acids and has a 10-50 times higher Ca2+-binding affinity than
the 14–amino acid containing N-terminal, S100-specific pseudo–
EF-hand [20]. Between these two EF-hands is a hinge spanning 10-12
amino acids [20], which is replaced by multiple tandem repeats in the
SFTP family [21]. Upon binding of Ca2+, the proteins undergo
conformational changes, which expose hydrophobic amino acids in the
first helix of the C-terminal EF-hand and in the hinge region, which in
succession interact with hydrophobic patches of the target protein
[13,22]. The affinity towards calcium is increased up to 300 times
during this process [23,24]. Since the hydrophobic interaction is
essential for ligand recognition, the hydrophobic patches of S100
proteins are the regions with the lowest sequence similarities among its
members [20].
Most S100 proteins are Ca2+ sensors and will bind targets, and
thus translate the changes in intracellular calcium concentrations intoresponse, after influx of Ca 2+ through voltage-gated or
receptor-mediated channels [22]. Others, like S100G [15], are Ca2
+ buffers and control calcium homeostasis, but the boundaries
between these two groups appear to be more blurred than initially
assumed [22].
S100 proteins have a wide variation of functions; the reasons for that
are: 1) tissue-, cell-, and time-dependent expression [13,22]; 2)
dimerization and oligomerization with different partners [16]; 3)
binding of different metal ions and with varying affinities [16]; 4)
posttranslationalmodifications [13]; and 5) employment of intracellular
functions, extracellular functions, or both [22]. Among important
intracellular functions are the regulation of cell proliferation, cell
differentiation, and apoptosis [15], in addition to targeting enzymes,
subunits of the cytoskeleton like F-actin and myosin, nucleic acids, and
transcription factors [16,25]. Outside the cells, the S100 family
interacts with a variety of receptors, with the most important being
G-protein–coupled receptors, scavenger receptors such as CD36 [15],
toll-like receptor 4 (TLR4) [26], and the S100 general receptor for
advanced glycation end products (RAGE) [16]. The latter, in turn,
induces the formation of reactive oxygen species (ROS) and activates
MAPK pathways, NFκB and Stat3, the PI3K-Akt-mTOR pathway,
and small GTPases [16,27]. S100 proteins also act as cytokines or
damage-associated molecular patterns (DAMPs or alarmins) themselves
[28] as they are involved in processes such as induction of cytokines and
growth factors, activation of both the innate and adaptive immune
system, chemotaxis and cell migration, and tissue development and
repair [15,25]. Figure 1 highlights the S100 downstream signaling
pathways with most impact on tumorigenesis but also anticancerous
effects such as cell differentiation.
With regard to all these diverse functions, of which many are
essential in cancer development and progression, and the fact that
S100 proteins are prone to genetic rearrangements at 1q21, it may not
come as a surprise that S100 proteins frequently are dysregulated in
cancer [13].
S100 Proteins in Tumorigenesis
There is now consensus that cancer results from the interaction
between tumor cells (the seed) and themicroenvironment (the soil). This
interaction drives processes necessary for cancer progression, such as
tumor cell growth, angiogenesis, and tumor invasion. Cross talk between
tumor cells and stromal elements, e.g., through cytokine secretion, may
also stimulate cancer cell growth but in addition remodels the stromal
niche towards a tumor-promoting environment [29]. Furthermore,
tumor cells can attract immune cells, e.g., leukocytes, which secrete
growth factors and cytokines that either might support the tumor niche
or inhibit functionally competent immune cells [29]. The processes
involved inmetastasis are similar to those of primary tumors, and both are
often preceded by chronic inflammation [29]. Regarding AML, one may
use the term “niche-driven oncogenesis” as remodeling of the
mesenchymal niche can induce cytogenetic alterations in hematopoietic
stem cells (HSCs), eventually resulting in AML [30].
S100 proteins contribute to tumorigenesis and metastasis in various
ways. Members of the S100 family can provide a local inflammatory
environment for cancer development and progression [20]. S100B
upregulation in malignant gliomas, for instance, induces CCL2
expression and subsequently enhances infiltration of tumor-associated
macrophages, which are important components in inflammation [31].
As soluble mediators, S100 proteins themselves are involved in the cross








































Figure 1. Important S100 signaling pathways. Most S100 proteins signal via the RAGE receptor, whereas a small selection also signals via
TLR4. The pathways sum up the most important downstream signaling effects of S100A8 and S100A9, the most thoroughly studied S100
proteins. S100A8 can induce autophagy via RAGE, while S100A9may induce cell differentiation via TLR4/Erk-signaling. Additionally, many
S100 members can bind p53; the figure highlights the three proteins that are recognized inhibitors of the tumor suppressor.
Neoplasia Vol. 20, No. 12, 2018 S100 Proteins in Acute Myeloid Leukemia Brenner and Bruserud 1177chemoattractants. An example for this behavior is S100A4: tumor cells
induce the secretion of this mediator from stromal fibroblasts [28].
S100A4 then modifies the tumor microenvironment through its
function as chemoattractant which leads to macrophage and T-cell
infiltration into the tumor niche [29]. Furthermore, S100 proteins can
exhibit their tumorigenic effect through receptor binding and
downstream signaling [29]. The RAGE receptor for instance is
expressed on many cells in the tumor environment, e.g., endothelial
cells and fibroblasts [27].
Dysregulation of S100 proteins is a common feature in cancer, and
in most cancers, the protein expression is upregulated [13]. It appears
as if every type of cancer has its specific S100 profile, and the latter
may also vary among different stages and subtypes within a
malignancy [13]. S100 profiling for cancer is further complicatedby the fact that S100 protein overexpression also is associated with
various noncancerous conditions, such as cardiovascular, neurolog-
ical, and inflammatory diseases [13]. In some cancers, individual
S100 proteins even appear to act as tumor suppressors [32,33].
In recent years, reviews on the role of the S100 protein family in
various types of cancers, e.g., breast [34,35], pancreatic [27],
colorectal [22], and lung cancer [36], have been published. This
review aims to address the role of S100 proteins in hematological
malignancies, with a special focus on AML.
S100 Proteins in AML
This chapter focuses on those members of the S100 and SFTP
families which have been studied in AML and in three related
malignancies: 1) chronic myeloid leukemia (CML) which in blast
Table 1. Observed Effects of S100 Protein Family Member Up- or Downregulation in Leukemias
Mediator * ALL AML APL CML MDS
S100A4 ↑ In pediatric AML [40]; down-





S100A6 ↑ MLL/AF4: inhibits p53 and 
TNFα-induced apoptosis [50]
prevents graft vs. leukemia
effect [49]
Reported in AML [47, 48]
S100A8 ↑ At diagnosis and relapse, induces
autophagy [56, 57]; high white 
blood count, shortened overall
survival, prevalent in FAB 





S100A9 ↓ Differentiation arrest,
reduces apoptosis,
due to PML/RARA [65]
↑ Blast differentiation if low
S100A8 levels [55]







blast mobilization [55]; high
LSC frequency [74]; most
upregulated genes in AML, drug 
resistance [75]; GvHD [77]
In MDS-MSCs: upregulates
p53 and TLR4; represents
a high-risk subset among
low-risk patients [30]
S100A10 ↑ Protects blasts from cytotoxic agents by osteoblast homing [82]
Coagulopathy [80, 81](tetrameric) Early relapse [82]
S100B ↑ Prevents sympathetic nerve
injury, pro longed survival [97]
S100P ↑ Favorable, induces differentiation
[98-100]; enhances survival during 
stress, drug resistance, favors
secondary AML development 
[101]
Favorable, induces
differentiation  [98, 
100]
Hornerin ↑ t(1;2): MDS to AML
transformation [102]
* Up- or downregulated as compared to healthy controls.
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leukemia; and 3) MDS, which resembles a preleukemic state where
approximately 30% of the patients progress to AML. It is likely that
S100 protein features in these malignancies will be comparable to the
effects in AML. We will also include the effect of S100 protein
expression on stromal cells, which interact with leukemic cells in the
bone marrow niche. The most prominent effects on different types of
leukemia are summarized in Table 1.
S100A2
The effect of this mediator has, to our knowledge, not been studied
in leukemia. However, it is an intriguing protein as it has been
described both as tumor suppressor and as initiator of tumorigenesis
and metastasis dependent on the cancer type. Its function as
chemoattractant and its contradictory role as either inhibitor or
inducer of p53 depending on the studied system [20,37] might also
be of importance in hematological malignancies.
S100A4
The protein was originally named “metastatin,” highlighting its
importance in metastasis. S100A4 is infamous in cancer, as its
expression is widely accepted to be a marker for poor prognosis
[15,20,29] and resistance towards treatment [27,38]. It exerts its
prometastatic function by being a negative regulator of p53, positive
regulator of cell migration, and stimulator of angiogenesis [20,29].
However, S100A4 appears to only have minor effect on tumor
initiation and progression [39].
S100A4 has been studied in both AML and CML. An early study
showed that S100A4 mRNA expression in 52 pediatric AML patientswas three-fold higher than in healthy controls [40]. Another group
proposed a possible mechanism for why the expression of the
repressor of retinoic acid signaling (PRAME) is a positive prognostic
factor in leukemias as opposed to solid tumors [41]. PRAME is
overexpressed in, among others, AML [42,43], while it is very low in
normal CD34+ cells [40], and high expression is correlated with both
increased overall and event-free survival [44,45] and reduced risk for
relapse [41]. High PRAME expression downregulates S100A4 and
subsequently increases p53 activity and apoptosis in the AML cell line
KG-1. Knockdown of PRAME, on the other hand, rescued S100A4,
thus sequestering and disabling of p53 in K562 (CML cell line in
blast crisis). It was also shown that S100A4 expression has influence
on chemosensitivity in CML [38]: K562, which showed low
constitutive expression of S100A4, was more chemosensitive towards
4-hydroperoxy-cyclophosphamide than KU812, which expresses
higher S100A4 levels. Furthermore, the treatment itself increased
S100A4 levels in the cell lines [38].
S100A4 might also exert an effect on leukemic cells through the bone
marrow niche because the protein is expressed by the tumor stroma
[13,36]. Among the expressing cells are also mesenchymal stem cells
(MSCs), and S100A4 might be involved in MSC differentiation and
proliferation [39].
S100A6
This is another member of the S100 family whose upregulation is
linked with cell proliferation and tumorigenesis [15,20] in many
cancers, but also low expression is occasionally observed [46]. One
interesting mechanism is the relationship between S100A6 and the
tumor suppressor p53. The latter indirectly regulates S100A6
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by mutated p53 is a reason for S100A6 overexpression and increased
proliferation in cancer. On the other hand, S100A6 appears to
protect wild-type p53 from degradation and thus contribute to
apoptosis [46].
In hematological malignancies, increased levels of the protein have
been reported in AML [47,48]. The effect of S100A6 expression has
thoroughly been studied in acute leukemias with rearrangements in
the mixed-lineage leukemia (MLL) gene [49–52]. Chromosomal
aberrations in 11q23 are common in acute leukemias and especially
in infants and leukemia secondary to treatment with DNA
topoisomerase II inhibitors [49,51]. The prognosis of MLL
rearrangements is highly dependent on the chromosomal partner,
and more than 70 have been identified so far [49]. In their studies,
Tamai and coworkers have concentrated on the MLL/AF4 fusion
gene, t(4;11)(q21;q23), which is the most prevalent translocation in
ALL, accounting for more than 50% of infant and about 7% of adult
ALL. The prognosis for t(4;11) is poor, even following allogeneic
stem cell transplantation (allo-SCT), and thus represents the largest
challenge in childhood ALL [49–51]. In their studies, the group
identified the various roles of S100A6 in the malignancy. First, t(4;11)
requires a “second hit” to initiate leukemia; especially mutations in the
Flt3 tyrosine kinase domain (Flt3-TKD) are potent second hits.
Compared to only t(4;11), S100A6 expression is increased 13-fold
when t(4;11) is combined with Flt3-KTD. Knockdown of S100A6 on
the other hand inhibited leukemic proliferation [52]. Second, high
S100A6 expression can inhibit TNFα-induced apoptosis through its
inhibition of p53 acetylation and subsequent repressed upregulation of
the caspase 8-caspase 3 apoptotic pathway. This effect was exclusively
observed in cell lines with t(4;11). The results were confirmed in mouse
models of t(4;11) lymphoma [50]. Third, the S100A6-targeting drug
Amlexanox rescued p53-caspase 3 initiated apoptosis upon TNFα
treatment in t(4;11) cell lines. In mice, the inhibitor could counteract
leukemic infiltration in t(4;11) B-cell leukemia and inhibited the
upregulation of S100A6 [51]. Finally, knockdown of S100A6 in
murine models showed to induce graft versus leukemia (GvL) effect
after allo-SCTwhich is mainly mediated by TNFα; thus, the absence of
the GvL effect might explain why prognosis is poor in t(4;11) ALL even
following allo-SCT [49]. Inhibition of S100A6 might therefore be a
promising strategy for patients with MLL genetic rearrangements or
high constitutive S100A6 levels.However, S100A6 is almost exclusively
expressed in proliferating cells [22,36]. Therefore, quiescent cells in the
bone marrow might escape S100A6 inhibition and ultimately lead to
relapse.
S100A7/S100A7A
S100A7 is among the proteins that in some cancers are reported to
be tumor suppressors, while they appear to be involved in metastasis
in other cancers [20]. These two proteins may play a role in AML as
they are chemotactic for granulocytes, monocytes, macrophages, and
lymphocytes [15,20] and induce the secretion of proinflammatory
cytokines [28].
S100A8 and S100A9
Of the S100 protein family, these two members have been most
thoroughly studied in AML. The homodimers are less abundant than
the heterodimer S100A8/A9 due to lower stability of the former.
However, the two individual proteins appear to play quite contradictoryroles in AML; thus, this chapter will discuss S100A8, S100A9, and the
heterodimer separately.
S100A8
S100A8 is a marker for myeloid cell differentiation as it is expressed
by normal CD34− bone marrow cells but not by immature
myelocytes/blasts [53,54]. At proinflammatory conditions or during
oxidative stress, S100A8 can be induced in macrophages, dendritic
cells (DCs), microvascular endothelial cells, and fibroblasts [15]. In
general, S100A8 appears to play a role in leukemogenesis as a
regulator of myelopoiesis, where the protein contributes to
maintaining the undifferentiated phenotype [55].
In both childhood and adult AML studies (31 and 189 patients,
respectively), S100A8 bone marrow mRNA levels were significantly
higher at diagnosis and relapse as compared to healthy controls or
patients in complete remission and, thus, indicated the clinical status
of the disease [56,57].
The role of S100A8 has been studied by proteomics in childhood
AML with a normal or rare/noninformative karyotype, defined as
intermediate risk. High S100A8 levels correlated with white blood
count and shorter overall survival [54]. In a larger patient cohort,
S100A8 levels were also linked with cells with morphological signs of
differentiation as patients classified as FAB M4/M5 (monocytic
differentiation) had significantly higher levels than FAB M0/M1 (no/
minimal differentiation) [57]. Further, overall survival in patients
with a normal karyotype resembled that of adverse or favorable
cytogenetics depending on high or low S100A8 mRNA expression
levels, respectively. Finally, HL-60 cells with low initial S100A8 levels
showed increased expression after treatment with etoposide in a
dose-dependent matter, which interfered with the effect of the drug
[57].
This drug-resistant effect of S100A8 appears to be caused by autophagy
— the metabolic process in which intracellular aggregates, misfolded
proteins, or damaged organelles are degraded by lysosomes in response to
cellular stress [58]. Autophagy is recognized as important for
therapy-related resistance in hematological malignancies [59–62] as it is
induced byDNA-damaging agents, radiotherapy, andmolecular targeting
[56]. In supernatants fromHL-60 and K562, S100A8 was increased after
treatment with vincristine, adrenomedullin, and As2O3. When S100A8
expression was inhibited, chemosensitivity and apoptosis were increased,
while autophagy was reduced. The authors showed that S100A8-induced
ROS production is essential for autophagy in AML (Figure 1) through
disruption of the interaction between Bcl-2 and Beclin1 [56]. In a
follow-up study, S100A8 mRNA overexpression in leukemic cell lines
indicated to be linked with drug resistance and increased basal autophagy
[63].
Finally, S100A8 appears to be negatively correlated with both
treatment and sustained long-term major molecular response also in
CML in a study with 37 patients and might therefore be a marker for
aggressiveness, i.e., progression towards blast crisis [64].
S100A9
Like S100A8, also S100A9 is a marker of myeloid differentiation
and is increased in granulocytes and monocytes [65,66]. But unlike
S100A8 which signals via RAGE, S100A9 mainly signals via TLR4
[15] and can also associate with CD147/basigin [67,68]. The
receptors lead to the induction of proinflammatory cytokines such as
IL-6, CXCL8, and TNFα, and matrix metalloproteinases [13,15,25].
S100A9 is widely acknowledged to be involved in tumorigenesis, as it
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macrophages and DCs [28,69]. However, recent studies show
divergent effects for S100A9 in AML.
In APL, the FAB M3 AML subtype, S100A9 shows the lowest
gene transcribes among all FAB classes [65]. S100A9 levels are
inversely correlated with expression levels of PML/RARA, the fusion
gene, which defines APL. Upon treatment with all-trans retinoic acid
(ATRA) and, to a lesser degree, with As2O3, S100A9 expression levels
increase. Furthermore, higher S100A9 mRNA levels correlated with
higher expression of PU.1, an important transcription factor for
myeloid differentiation [65]. The results were confirmed in the APL
cell line NB4, where higher levels of S100A9 induced apoptosis
through reduced Bcl-2 levels and cleavage of caspase 3, and leukemic
cell growth suppression. Thus, at least in APL, higher S100A9 levels
are linked with myeloid differentiation, leukemia growth suppression,
and increased treatment response [65].
Also in non-APL AML, high S100A9 levels were correlated with
myeloid differentiation, but this ability was dependent on S100A8
expression levels [55]. S100A9 had to exceed S100A8 concentrations
by at least 10-fold; otherwise, S100A8 blocked differentiation. The
authors argue that the differentiation potential is mediated by TLR4
because the downstream kinases Erk1/2 and JNK are known to be
important for granulocyte and monocyte differentiation [55].
However, treatment with exogenous S100A9 induced leukemia cell
differentiation only in FAB M4/M5 patients, which according to
mRNA data also showed the highest basal levels of S100A8, S100A9,
and TLR4 [55]. Thus, the S100A9-TLR4-MAPK/Erk axis might be
a potential target for overcoming differentiation arrest in cells
presenting a monocytic phenotype (Figure 1).
S100A8/A9
Since the mRNA levels of the individual partners of the
heterodimer calprotectin appear to have opposing effects in AML,
it might not come as a surprise that the studies of the heterodimer
show conflicting results. First, S100A8/A9 is overexpressed in many
cancers [55] and associated with inflammation as it is an activator of
monocytes and macrophages, and leads to neutrophil infiltration
[20]. Through the characteristics of its individual partners, S100A8/
A9 can signal via both TLR4 and RAGE and promotes tumor
development and invasiveness both by increasing cell growth,
including leukemic cell proliferation, via RAGE and by excretion of
proinflammatory cytokines via TLR4-NFκB [15]. Interestingly,
S100A8/A9 is also associated with an anti-inflammatory effect,
reduced cancer growth, and apoptosis. The tetradimer can induce the
latter by sequestering Zn2+, which is antiapoptotic [70]. The
tumor-promoting effects appear in most cancers to be valid only for
low S100A8/A9 levels [71]; at high concentrations, several cells
(macrophages, bone marrow cells, lymphocytes, and fibroblasts) are
inhibited, and apoptosis is induced [22,25,72].
In the already mentioned MLL/AF4 ALL, S100A8/A9 overexpres-
sion was associated with failure to induce free cytostatic Ca2+ and
with corticosteroid resistance [73]. In AML, S100A8/A9 mRNA
levels increase during AML progression and show correlation with
mobilization of leukemia cells from the bone marrow into peripheral
blood [55]. Furthermore, S100A8 and S100A9 were the most
upregulated genes in patients with the highest frequencies of leukemic
stem cells [74], indicative of an adverse prognosis. A recent study
showed that the mRNA levels of S100A8/A9 are the most
overexpressed as compared to healthy controls [75]. High levelswere linked with resistance towards the novel drugs quizartinib (Flt3
inhibitor) and especially venetoclax (Bcl-2 inhibitor), which resulted
in the absence of free cytosolic Ca2+ and inhibition of apoptosis in cell
line studies [75]. Another study came to opposite conclusions:
S100A8 and especially S100A9 were among the most downregulated
genes as compared with healthy controls [76]. However, the latter
study focused on FAB M1/M2 (little or granulocytic differentiation)
patients who present with lower S100A8/A9 basal levels than blasts
with monocytic differentiation [55], and S100A9 could then be used
to distinctively differentiate FAB M1 from FAB M2 [76].
Nevertheless, the authors were able to reproduce their results, i.e.,
consequently downregulated S100A8/A9 in AML, analyzing micro-
arrays (GDS acquisitions: 1059, 2251, and 3057) deposited online
[76].
S100A8/A9 and, to some extent, also S100A7 and S100A12 are
furthermore among theDAMPswhich are associatedwith development
of graft versus host disease (GvHD) after allo-SCT, a potentially lethal
complication in which donor T-cells attack host tissues. But it remains
unclear whether elevated S100 protein levels in monocytes after
allo-SCT initiate GvHD or whether their increase rather results from
release from necrotic/apoptotic cells after establishment of GvHD
[77,78]. As a remark, these elevated S100A8/A9 levels were not
detected in blood samples but in saliva and stool [77,79].
The role of the DAMPs S100A8 and S100A9 has also been studied
in the tumor environment of the preleukemic conditions
Schwachman-Diamond syndrome (SDS) and MDS [30]. In SDS,
downregulation of the affected Sbds gene in MSCs leads to
upregulation of both p53 and S100A8/A9, with the subsequent
activation of TLR4-MAPK/NKκB. S100A8/A9 upregulation was
sufficient to induce genotoxic stress in HSCs [30], increasing the
propensity for AML progression. Also in MDS, S100A8/A9 MSC
expression was correlated with p53 and TLR4 upregulation.
Furthermore, in a cohort consisting of low-risk MDS patients, high
S100A8/A9 levels resulted in approximately doubled (corresponding
to almost 30%) risk for AML transformation, as well as the time
interval for AML development was significantly reduced [30]. It
appeared as if the MSC expression level of S100A8/A9 in these
syndromes was more important than that of myeloid cells. In
addition, the protein expression was observed in a specific subset of
CD271+ MSCs, which in the bone marrow are in direct contact with
CD34+ HSCs; thus, spatial proximity to the source of S100A8/A9
seems to be of importance [30].
S100A10
This particular S100 family member has mutations in its EF-hands
rendering it Ca2+-independent and thus permanently activated
[15,17]. It exerts its main biological function in a heterotetrameric
complex together with annexin 2 [17,20,80].
In AML, S100A10 is associated with coagulopathy in FAB M3
patients [80,81]. Approximately 5% of APL patients die early due to
severe bleedings, and up to 90% of patients suffer from coagulopathy
at diagnosis [81]. The S100A10/annexin 2 heterotetramer is elevated
in APL cells; at the cell surface, the tetramer increases the affinities of
urokinase and especially tissue plasminogen activators (uPa and tPa)
for their substrate plasminogen, which thereafter is converted to active
plasmin. The latter leads to hyperfibrinolysis, i.e., plasmin-mediated
degradation of the extracellular matrix, which in turn can cause
extensive bleeding [80,81]. As much as 90% of the observed plasmin
concentration seems to be due to S100A10 [80]. The fusion gene
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S100A10. However, the concentrations of both proteins increase,
indicating posttranslational regulation of S100A10 by elevated
annexin 2 levels [81]. Depletion of S100A10 or downregulation of
PML/RARA by ATRA in NB4 cells had approximately the same effect
and reduced both plasmin formation and fibrinolysis [80]. In
addition, in nine patients with de novo APL, either treatment with
ATRA or with an S100A10 antibody before APL therapy reduced
blast invasiveness [81]. Thus, downregulation of S100A10 might be
the reason why the risk of death from severe bleeding immediately
declines after the first dose of ATRA in APL patients.
S100A10 further seems to play a role in protecting acute leukemia
cells from cytotoxic agents. Annexin 2 leads to homing to the bone
marrow and adhesion of HSCs to osteoblasts [82]. The latter are known
to protect primary ALL and AML blasts from chemotherapy [83]. In
this respect, elevated S100A10 mRNA levels were identified in
childhood B-cell ALL, and increased levels also correlated with early
relapse [82]. Thus, inhibition of annexin 2, S100A10, or the formation
of the heterotetramer might be a means of overcoming treatment
resistance and early relapse in a patient subset.
S100A12
S100A12 is expressed by a variety of myeloid cells and induces
chemotaxis of leukocytes, but not lymphocytes, after binding to RAGE
[20,84]. It is associated with chronic inflammation through sustained
recruitment ofmonocytes and neutrophils andmight therefore also play
a role in hematological malignancies. S100A12 expression can be
induced by lipopolysaccharide (LPS) and TNFα, and—when it acts as
a cytokine — its effects are comparable to those of CCL2, CCL3,
CCL4, and CCL5 [84], i.e., cytokines that commonly are increased in
AML and of which CCL5 has been linked with cancer progression in,
e.g., lymphoma [85].
S100A13
This protein has not been extensively studied in leukemia. However,
the S100A6 inhibitor Amlexanox additionally targets S100A13 [51].
During stress, S100A13 induces the excretion of, among others, acidic
fibroblast growth factor (aFGF) and contributes to cancer hallmarks as
angiogenesis, cell differentiation, and tumor growth [15,51]. Since
Amlexanox inhibits the heat-shock protein (HSP)–induced release of
S100A13 [86] and HSPs are commonly expressed in AML and their
expression additionally increased when the blasts undergo apoptosis
[87,88], the downstream effects of S100A13 might contribute to
leukemogenesis or to maintaining the disease.
S100A16
S100A16 might exert an indirect effect on AML. As with many other
S100 proteins, also S100A16 is upregulated in several types of cancer [15].
It might play a role in the bone marrow niche because S100A16 inhibits
osteogenic differentiation of MSCs in expense of adipogenesis [89]. Both
MSCs and osteoblasts have shown to protect AML blasts from
chemotherapy [83,90], but also bone marrow adipocytes appear to exert
effects on leukemic cells: adipocytes provide energy and have shown to
protect both ALL and CML blasts from chemotherapy [91–93].
However, AML itself causes MSCs to differentiate towards osteoblasts
rather than to adipocytes [94]. Thus, high S100A16 levels in the bone
marrow niche might alter the cross talk between the MSC progeny and
AML cells, but more research is necessary in order to uncover if this
alteration will result in improved or worsened prognosis.S100B
This S100 protein is mainly linked with neurological disorders and
is for instance upregulated in brain metastasis [36]. However, it is also
a metastatic marker in other cancers and is then one of the S100
proteins with contradictory prognostic impact depending on the
cancer type. In breast cancer, high S100B levels are correlated with
better outcome in the endocrine-resistant negative subtype [95],
whereas increased posttreatment levels in the endocrine-resistant
positive subtype are linked with reduced survival [96].
S100B is further expressed by DCs and lymphocytes and leads to
increase in cell proliferation and migration, while inhibiting apoptosis
and differentiation [15]. In AML, S100B expression in bone marrow
neural tissues seems to be of importance because sympathetic nerve
injury is closely related to hematological diseases [97]. S100B is a
marker for nonmyelated Schwann cells, which are part of the healthy
bone marrow niche, where they facilitate HSC hibernation. Damage
of these cells can lead to AML progression. In concurrence with that,
elevated S100B mRNA levels in AML showed a correlation trend
towards prolonged patient survival [97].
S100P
As many other S100 proteins, also high S100P levels are associated
with cell growth, carcinogenesis, and metastasis [20,22,27]. However,
like for S100B, elevated S100P levels appear to be favorable in AML.
S100P is transiently expressed during early leukocyte differentiation
and is probably essential in this process [98]. In agreement with that,
S100P shows low expression in K562 [38] and in AML blasts, whereas
high levels are connected with a favorable prognosis [99]. S100P has
mainly been studied in association with cytokinins in the treatment of
AML. Cytokinins are purine derivatives that act as hormones in plants
but which also exert antiproliferative effects in cancer cells and induce
granulocyte differentiation in myeloid leukemias through activation of
MAPK [98]. Different kinds of cytokinins and their derivatives
(isopentenyladenosine, cotylenin A, methyljasmonate, and 4,5-didehy-
drojasmonate) had in cell line studies (AML:HL-60, THP-1; APL:NB4;
lymphoma: U937) approximately the same effects with regard to
granulocytic/monocytic differentiation as ATRA and vitamin D3
[98,100]. But the similar effects were mediated through different
mechanisms, as S100P was the most upregulated gene only after
treatmentwith cytokinins [98,100]. Thus, induction of S100P expression
might be a possiblemeans to counteract the differentiation arrest in AML.
On the other hand, S100P has been proposed to play a role in the
cellular defense mechanism and to enhance survival under stress [101].
Treatment-related MDS — and further transformation to AML — is
seen after cytotoxic therapy with bifunctional alkylating agents that
form DNA interstrand cross-links. When HL-60 was exposed to this
type of alkylating agents at a low dosage, thus facilitating recovery of cell
growth, S100P showed the highest increase in mRNA levels [101]. The
elevated levels led to cell cycle arrest at the G2/M transition point, and it
took about 10 days to resume cell growth. Furthermore, the cells were
then resistant to reexposure of the drug [101]. Thus, S100P might be
involved in processes leading to survival of cells with DNA interstrand
cross-links, which later on might initiate hematological malignancies.
However, it must be pointed out that not all tested cell lines responded
in the same way as HL-60 [101]. Hence, dosage of the alkylating agents
appears to be of major importance.
S100Z
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S100P and is, together with its partner, highly upregulated by
alkylating agents, with the highest levels reported in leukocytes andspleen [101]. S100Z might therefore play a role in the
S100P-mediated effects on cell survival during stress.
Hornerin
Of the seven SFTPs, hornerin is the one which to the highest
degree appears to be involved in other processes than epidermal
maturation and skin/mucosa cancers.
The relation between hornerin and AML was demonstrated in a
case study. This particular patient presented with the rare
chromosomal alteration t(1;2)(q21;q37) and had recently progressed
from MDS [102]. Thus, the translocation was situated at 1q21 where
most S100 proteins and the SFTP family are encoded. Chromosomal
alterations, including duplications and translocations in 1q21-25,
which result in gene degeneration or fusion genes that interfere with
normal proliferation and differentiation, are frequently detected in
hematological malignancies. In this case, the translocation did not
interrupt the hornerin open reading frame but resulted in its aberrant
expression in bone marrow cells. Additional 5 out of 90 patients
suffering from hematological diseases showed elevated hornerin
mRNA levels [102]. The authors speculate 1) that S100 fusion genes
may be involved in neoplasia, 2) that translocations have an effect
similar to activation of an oncogene, and 3) that hornerin activation
was responsible for disease progression for the t(1;2) patient [102].
The latter notion is supported by studies on breast and liver cancer,
where hornerin expression levels increased from the preinvasive phase
to the invasive carcinoma [21] or were correlated with poor outcome
in hepatocellular carcinoma [103], respectively.S100 Proteins as Biomarkers in AML: Potential and
Pitfalls
Like in many other cancers as well as noncancerous conditions, the
expression of S100 proteins appears to be altered in AML.
Overexpression of S100A4, A6, A8, A9, A10, and A12 and
downregulation of S100P seem to maintain the leukemic phenotype.
More extensive studies will have to be conducted in order to
determine whether one single member of this family or rather a panelFigure 2. High S100 protein expression is associated with
increased patient survival. (A) Only patients who received intensive
induction therapy were included in the cluster; the mRNA levels
were median normalized and log(10) transformed prior to
unsupervised clustering using the program JExpress. Patients
could be divided into two main subgroups according to low
(patients L1-L12) and high (patients H1-H10)/intermediate (patients
I1-I6) mRNA expression levels. The upper/low expression subgroup
showed especially low (blue color) S100A8/A9 expression,
whereas the group below, characterized by high expression,
showed especially elevated (red color) levels for S100A12 and
S100P. Patients with long-term survival (N2.5 years) are indicated
to the right. The S100A4 and A10 values represent the mean value
of two probes for these genes. B) Kaplan-Meier (calculated by
SPSS version 25) comparison of patients with low S100 protein
expression (L1-L12) versus patients with median or high levels, i.e.,
the two subgroups obtained in the cluster. In this patient cohort,
elevated levels of S100 proteins are correlated with prolonged
patient survival (log-rank test). Because the plot takes into account
all eight differently expressed S100 proteins, the improved patient
survival might be due to the impact of a single S100member, to the
whole panel of these eight proteins, or to a group of co-expressed
genes, which remain to be identified yet.
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progression, and treatment response.
At least two caveats arise from this review. First, S100 protein
expression levels have been determined with different techniques, and
the latter were conducted on samples obtained from various sources.
Gene expression, both by microarray and PCR techniques, has been
measured in both peripheral blood blasts and bone marrow cells.
Furthermore, protein expression was detected using Western blotting,
immunostaining, ELISA, flow cytometry, or proteomic techniques,
and samples comprised peripheral blood cells, bone marrow cells,
primary cell culture supernatants, serum, plasma, saliva, and stool.
Protein expression is regulated both posttranscriptionally and
posttranslationally, and proteins are further prone to modifications
which alter their function. Even though there is a correlation between
mRNA and protein levels, this connection is not strong, and about
60% of protein concentrations are not reflected by the mRNA levels
[104,105]. An example is the deviation between S100A10 gene versus
protein expression levels [81]; thus, one should be careful when
comparing protein with gene expression levels. Also, sample source
can influence expression levels. A recent example is osteopontin: high
serum/plasma osteopontin levels are a recognized negative prognostic
marker in AML [106,107]; however, osteopontin seems to be
upregulated in cell culture supernatants of patients with prolonged
survival [108]. Therefore, when implementing S100 proteins as
biological markers in AML, sample source and selected method will
have to be standardized. Second, the expression levels of several of the
S100 proteins are correlated with cell maturation/differentiation.
Particularly, S100A8 and A9 are associated with FAB M4/M5. Thus,
at some occasions, upregulated S100 proteins will not be correlated
with pathology but simply reflect the AML phenotype.
In a recent study, we observed that mRNA levels for S100A6, A8,
A9, and A11 were upregulated in AML patients with high cell culture
supernatant concentrations of specific proteases and protease inhibitors,
including CD147/basigin — a S100A9 receptor — and the
S100A10-related uPa [109]. Like S100A9, basigin was found to be
overexpressed in FAB M4/M5 patients and the more mature CD34−
cell fraction and was additionally correlated with an upregulation of
S100A4 and the S100A9 receptor TLR4 [109]. Interestingly, there was
a large overlap between the patients with high cellular expression of
proteases and those with a high cytokine excretion profile, where the
latter had been linked with improved survival [110]. Therefore, we
analyzed whether S100 protein mRNA expression also was correlated
with survival. Even though only 28 of the patients from the microarray
study qualified for inclusion in the analysis, the 12 patients with low
S100 protein mRNA levels (Figure 2A; previously unpublished data)
had a significantly (P b .0001, log-rank test) shorter survival compared
to the patients with higher levels (Figure 2B). Eight of the S100 proteins
were differentially expressed among patients; of these, low levels of
S100A8 and A9 seem to correlate with an adverse phenotype, whereas
high levels of S100A12 and S100P appear to be linked with a more
favorable phenotype (Figure 2A).
To summarize, it might be advisable to use a panel of S100 proteins
as biomarkers instead of single members for several reasons. First, a
distinctive S100 protein profile is, in many cancers, stage and subtype
specific. Furthermore, the profile at diagnosis at its best can provide
information about prognosis and/or treatment options, whereas
monitoring of the protein profile can yield insight into treatment
response [13]. Second, even though there exist strong candidates for
single biomarkers, such as S100A4, A8, A9, and S100P, the expressionof single proteins is prone to bias due to specific AML subgroups or the
simultaneous presence of an AML-unrelated malignancy, which both
can lead to dysregulation of specific S100 members. Third, sampling of
a protein profile also takes into account that S100 proteins may be
co-expressed. Remarkably, even though most of the S100 family
members cluster together and have a high degree of sequence similarity,
the expression of S100 proteins is commonly not synchronized [111].
On the contrary, there is evidence that S100 protein dysregulation
during cancer is regulated by promoter hypo- or hypermethylation
[111]. In this respect, co-expression of S100A14 and A16 has been
observed in breast cancer and resulted in increased tumor invasion and
thus worsened prognosis [112]. Furthermore, nuclear co-expression of
S100A4 and p53 was seen in colorectal cancer. In combination with
TP53 wt, the cells underwent apoptosis. The authors therefore
speculated that S100A4 might select for cancer-promoting mutations
in TP53 [113]. Finally, as long as the role of particular S100 members
in AML remains unclear and not all aspects of their impact on other
molecules or pathways, such as the above-mentioned p53 which
frequently is dysregulated in AML [114], are resolved, a panel of
biomarkers offers the best possibility to capture those candidate
proteins, which define AML.
Conclusion
S100 proteins are frequently dysregulated in malignancies, including
AML. More studies on the effect of S100 proteins in AML have to be
undertaken in order to determine which members of the protein
family have the highest impact on leukemogenesis and from which
sample source gene and/or protein expression levels should be
obtained. Furthermore, since disease heterogeneity apparently blurs
some of the effects, which single mediators exert, it might be necessary
to concentrate the studies, at least at first, on patient subsets sharing
the same morphology (e.g., FAB classes), cytogenetic aberrations, or
other common features.Ethical Approval
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